No true canonical name; the phrase improperly joins two canonical entities: Phosphatidylinositol 3-kinase, Protein kinase B (Akt) (No single canonical abbreviation. Standard abbreviations: PI3K (for Phosphatidylinositol 3-kinase), Akt or PKB (for Protein kinase B))

Phosphatidylinositol 3-kinase (PI3K) and protein kinase B (Akt, also called PKB) are distinct enzymes that function together in the PI3K/Akt signaling pathway, which critically regulates cell proliferation, survival, metabolism, and growth. PI3K generates lipid second messengers (mainly PIP3) at the plasma membrane that recruit and activate Akt via phosphorylation by PDK1 and mTORC2. Activated Akt phosphorylates a wide array of substrates, impacting cell cycle progression, apoptosis inhibition, metabolic regulation, protein synthesis, and angiogenesis. The pathway is frequently dysregulated in cancer, driving uncontrolled cell survival and proliferation, and is therefore a major focus for therapeutic intervention with PI3K and Akt inhibitors. While these proteins are classically discussed together in the context of this pathway, they are distinct molecular entities and should be annotated separately for precise scientific communication.

Other names

PI3KAktPKBPI3K/Akt pathwayPI3K/PKB pathwayPhosphoinositide 3-kinaseProtein kinase B

Inhibition of PI3K blocks generation of PIP3, which suppresses Akt activation and downstream anti-apoptotic/signaling functions. Akt inhibitors directly block the kinase activity of Akt, preventing phosphorylation of downstream effectors and suppressing cell proliferation/survival